购物车
- 全部删除
您的购物车当前为空
(±)17(18)-EpETE-Ethanolamide
产品编号 T85120Cas号 2123491-23-4
别名 17,18-epoxy-Eicosatetraenoic Acid Ethanolamide, 17,18-EEQ-EA, (±)17,18-EEQ-Ethanolamide, (±)17(18)-EpETE-EA
(±)17(18)-EpETE-Ethanolamide, an ω-3 endocannabinoid epoxide, originates from eicosapentaenoic ethanolamide (EPEA) through cytochrome P450 (CYP) epoxygenases action and is decomposed by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FA, AH). Its endogenous synthesis occurs in LPS-stimulated and EPEA-supplemented BV-2 microglia cells, a process inhibited by the CYP inhibitor ketoconazole. This compound mitigates IL-6 and nitrite levels while enhancing IL-10 production following LPS exposure in BV-2 microglia. At a dose of 50 µM, it prevents platelet aggregation caused by arachidonic acid but not that triggered by ADP, collagen, or ristocetin. Additionally, it facilitates the dilation of constricted bovine coronary arteries (ED50= 1.1 µM) and blocks VEGF-driven tubulogenesis in human microvascular endothelial cells (HMVECs).
(±)17(18)-EpETE-Ethanolamide
产品编号 T85120 别名 17,18-epoxy-Eicosatetraenoic Acid Ethanolamide, 17,18-EEQ-EA, (±)17,18-EEQ-Ethanolamide, (±)17(18)-EpETE-EACas号 2123491-23-4
(±)17(18)-EpETE-Ethanolamide, an ω-3 endocannabinoid epoxide, originates from eicosapentaenoic ethanolamide (EPEA) through cytochrome P450 (CYP) epoxygenases action and is decomposed by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FA, AH). Its endogenous synthesis occurs in LPS-stimulated and EPEA-supplemented BV-2 microglia cells, a process inhibited by the CYP inhibitor ketoconazole. This compound mitigates IL-6 and nitrite levels while enhancing IL-10 production following LPS exposure in BV-2 microglia. At a dose of 50 µM, it prevents platelet aggregation caused by arachidonic acid but not that triggered by ADP, collagen, or ristocetin. Additionally, it facilitates the dilation of constricted bovine coronary arteries (ED50= 1.1 µM) and blocks VEGF-driven tubulogenesis in human microvascular endothelial cells (HMVECs).
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 询价 | 8-10周 | |
| 50 mg | 询价 | 8-10周 |
大包装 & 定制
加入购物车
实验操作小课堂
查看更多 联系我们获取更多批次信息
资源下载
产品介绍
生物活性
化学信息
| 产品描述 | (±)17(18)-EpETE-Ethanolamide, an ω-3 endocannabinoid epoxide, originates from eicosapentaenoic ethanolamide (EPEA) through cytochrome P450 (CYP) epoxygenases action and is decomposed by soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FA, AH). Its endogenous synthesis occurs in LPS-stimulated and EPEA-supplemented BV-2 microglia cells, a process inhibited by the CYP inhibitor ketoconazole. This compound mitigates IL-6 and nitrite levels while enhancing IL-10 production following LPS exposure in BV-2 microglia. At a dose of 50 µM, it prevents platelet aggregation caused by arachidonic acid but not that triggered by ADP, collagen, or ristocetin. Additionally, it facilitates the dilation of constricted bovine coronary arteries (ED50= 1.1 µM) and blocks VEGF-driven tubulogenesis in human microvascular endothelial cells (HMVECs). |
| 别名 | 17,18-epoxy-Eicosatetraenoic Acid Ethanolamide, 17,18-EEQ-EA, (±)17,18-EEQ-Ethanolamide, (±)17(18)-EpETE-EA |
| 分子量 | 361.52 |
| 分子式 | C22H35NO3 |
| CAS No. | 2123491-23-4 |
储存&溶解度
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
计算器
体内实验配液计算器
请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， 
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
预览
Related Tags: buy (±)17(18)-EpETE-Ethanolamide | purchase (±)17(18)-EpETE-Ethanolamide | (±)17(18)-EpETE-Ethanolamide cost | order (±)17(18)-EpETE-Ethanolamide | (±)17(18)-EpETE-Ethanolamide chemical structure | (±)17(18)-EpETE-Ethanolamide formula | (±)17(18)-EpETE-Ethanolamide molecular weight
嗨！很高兴为您提供帮助！
